Conventional and new antidepressant drugs in the elderly

Progress in Neurobiology

Volumn 61, Issue 4, 2000, Pages 353-396

  Gareri, Pietro ^a   Falconi, Umberto ^a   De Fazio, Pasquale ^a   De Sarro, Giovambattista ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Atypical antidepressants; Depression; Elderly; Lithium; MAO inhibitors; Pharmacodynamics; Pharmacokinetics; Tricyclics

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOSULEPIN; DOXEPIN; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; IMIPRAMINE; LAMOTRIGINE; LITHIUM DERIVATIVE; MAPROTILINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PHENYTOIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VALPROIC ACID;

AGED; AGING; DEPRESSION; DRUG INDUCED DISEASE; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; HIGH RISK PATIENT; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SUICIDE; TREATMENT INDICATION;

AFFECT; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; INCIDENCE; LIVER; MONOAMINE OXIDASE INHIBITORS; PREVALENCE; RECEPTORS, ADRENERGIC; RECEPTORS, DOPAMINE; RECEPTORS, GABA-B; RECEPTORS, SEROTONIN;

EID: 0034113372     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-0082(99)00050-7     Document Type: Review

References (349)

1. Abernethy D.R., Greenblatt D.J., Shader R.I. Imipramine and desipramine disposition in the elderly. J. Pharmac. Exp. Ther. 232:1985;183-188.
2. Abou-Saleh M.T., Coppen M.A. The prognosis of depression in old age: the case for lithium therapy. Br. J. Psychiatry. 143:1983;527-528.
3. Abramowski D., Rigo M., Duc D., Hoyer D., Staufenbiel M. Localization of the 5-hydroxytryptamine 2C receptor protein in human and rat brain using specific antisera. Neuropharmacol. 34:1995;1635-1645.
4. Alexanderson B., Price Evans D.A., Sjoqvist F. Steady state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. B. M. J. 2:1969;764-768.
5. Allen M.R. Sedativo-ipnotici ed ansiolitici anche nell'anziano. Geriatrics. 4:1987;51-58.
6. Altamura A.C., Moro A.R., Percudani M. Clinical pharmacokinetics of fluoxetine. Clin. Pharmacokinet. 26:1994;201-214.
7. Amato L., Paolisso G., Cacciatore F., Ferrara N., Canonico S., Rengo F., Varricchio M. Non-insulin-dependent diabetes mellitus is associated with a greater prevalence of depression in the elderly. The Osservatorio Geriatrico of Campania Region Group. Diabetes Metab. 22:1996;314-318.
8. Amrein R., Allen S.R., Guentert T.W., Hartmann D., Lorscheid T., Schoerlin M.P., Yranesic D. The pharmacology of reversible monoamine oxidase inhibitors. Br. J. Psychiatry. 155:1989;66-71.
9. 3H ]GBR 12935 binding in vitro to rat striatal membranes: labelling of the dopamine uptake complex. J. Neurochem. 48:1987;1887-1896.
10. 2 agonists in rats. Pharmac. and Toxicol. 64:1989;165-172.
11. 2A receptors in the rat medial prefrontal cortex: an ionophoretic study. Synapse. 17:1994;173-181.
12. Auster R. Sertraline: a new antidepressant. Am. Fam. Physician. 48:1993;311-314.
13. Balant-Gorgia E.A., Balant L.P. Therapeutic drug monitoring. Relevance during the drug treatment of psychiatric disorders. CNS Drugs. 4:1995;432-453.
14. Baldwin R.C., Tomenson B. Depression in late life. A comparison of symptoms and risk factors in early and late onset cases. Br. J. Psychiatry. 167:1995;649-652.
15. Barbhaiya R.H., Buch A.B., Greene D.S. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. Br. J. Clin. Pharmacol. 42:1996;573-581.
16. Bauer L.A., Davis R., Wilensky A., Raisys V.A., Levy R.H. Valproic acid clearance: unbound fraction and diurnal variations in young and elderly adults. Clin. Pharmacol. Ther. 37:1985;697-700.
17. Baumann P. Pharmacokinetic and pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin. Pharmacokinet. 31:1996;444-469.
18. Baumann P. Care of depression in the elderly: comparative pharmacokinetics of SSRIs. Int. Clin. Psychopharmac. 13:1998;35-43.
19. Bayer A.J., Pathy M.S. Identification of depression in geriatric medical patients. Ghose K. Antidepressants for Elderly People. 1989;13-25 Chapman and Hall, London.
20. Beasley C.M. Jr, Dornseif B.E., Pultz J.A., Bosomworth J.C., Sayler M.E. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J. Clin. Psychiatry. 52:1991;294-299.
21. Beers M.H., Ouslander J.G. Risk factors in geriatric drug prescribing. Drugs. 37:1989;105-112.
22. Ben-Arie O., Swartz L., Dickman B.J. Depression in the elderly living in the community. Its presentation and features. Br. J. Psychiatry. 150:1987;169-174.
23. Bennett D.A. Jr, Phun L., Polk J.F., Voglino S.A., Zlotnik V., Raffa R.B. Neuropharmacology of St. John's wort (Hypericum). Ann. Pharmacother. 32:1998;1201-1208.
24. Berkman L.F., Berkman C.S., Kasl S., Freeman D.H., Leo L., Ostfeld A.M., Cornoni-Huntley J., Brody J.A. Depressive symptoms in relation to physical health and functioning in the elderly. Am. J. Epidemiol. 124:1986;372-387.
25. Bersani G., Grispini A., Marini S., Pasini A., Valducci M., Ciani N. 5-HT2 antagonist ritanserin in neuroleptic-induced Parkinsonism: a double-blind comparison with orfenadrine and placebo. Clin. Neuropharmacol. 13:1990;500-506.
26. Bertilsson L., Dahl M.L., Sjoqvist F., Aberg-Wistedt A., Humble M., Johansson I., Lundqvist H., Ingelman-Sundberg M. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet. 341:1993;63.
27. Bertschy G., Luxembourger I., Bizouard P., Vandel S., Allers G., Volmat R. Amineptin dependence. Detection of patients at risk. Report of 8 cases. Encephale. 16:1990;405-409.
28. Blazer D. The diagnosis of depression in the elderly. JAGS. 28:1980;52-58.
29. Blazer D. Depression in the elderly. N. Engl. J. Med. 320:1989;164-166.
30. Blazer D., Burchett B., Service C., George L.K. The association of age and depression among the elderly: an epidemiologic exploration. J. Gerontol. 46:1991;210-215.
31. Blazer D., Williams C.D. Epidemiology of disphoria and depression in an elderly population. Am. J. Psychiatry. 137:1980;439-444.
32. Blier P., de Montigny C., Chaput Y. A role for the serotonin system in the mechanism of action of antidepressants. J. Clin. Psychiatry. 51:(4):1990;14-20.
33. Bolden-Watson C., Richelson E. Blockade by newly develop antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 52:1993;1023-1029.
34. Bosc M., Dubini A., Polin V. Development and validation of a social functioning scale, the social adaptation self-evaluating scale. Eur. Neuropsychopharmacol. 7:(1):1997;557-570.
35. 2 receptor mRNA. Brain Res. 564:1991;203-219.
36. Brosen K. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther. Drug Monitor. 18:1996;393-396.
37. Brunello, N., Langer, S.Z., Perez, J., Racagni, G., 1994/1995. Current understanding of the mechanism of action of classic and newer antidepressant drugs. Depression 2, 119-126.
38. ζ, pp. 16-28.
39. Brymer C., Winograd C.H. Fluoxetine in elderly patients: is there cause for concern? JAGS. 40:1992;902-905.
40. Buff D.D., Brenner R., Kirtane S.S., Gilboa R. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J. Clin. Psychiatry. 52:1991;174-176.
41. 2 dopamine receptor cDNA. Nature. 336:1988;783-787.
42. 2-adrenergic receptors. FASEB. 6:1992;832-839.
43. Caird F.I., Andrews G.R., Kennedy R.D. Effect of posture on blood pressure in the elderly. Br. Heart J. 35:1973;527-530.
44. Callahan C.M., Hendric H.C., Dittus R.S., Brater D.C., Hui S.L., Tierney W.M. Improving treatment of late life depression in primary care: a randomized clinical trial. JAGS. 42:1994;839-846.
45. Calvo B., Garcia M.J., Pedraz J.L., Marino E.L., Dominguez-Gil A. Pharmacokinetics of amoxapine and its active metabolites. Int. J. Clin. Pharmacol. Ther. Toxicol. 23:1985;180-185.
46. Caron M.G., Beaulieu M., Raymond V., Gange B., Drouin J., Lefkowitz R.J., Labrie F. Dopaminergic receptor in the anterior pituitary gland. J. Biol. Chem. 253:1978;2244-2253.
47. Caron M.G., Lefkowitz R.J., Hnatowitch M., Dohlman H., Bouvier M., Benovic J.L., O'Dowd B.F., Kobilka B.K., Hausdorff W.P. Structure and function of adrenergic receptor: models for understanding G protein coupled receptor. Iyengan R., Binnnbaumer L. G Proteins. 1990;295-316 Academic Press, Orlando, FL.
48. Carpiniello B., Carta M.G., Rudas N. Depression among elderly people. A psychosocial study of urban and rural population. Acta Psychiatr. Scand. 80:1989;445-450.
49. 5) in single neostriatal neurons. Soc. Neurosci. Abstr. 559:1995;11.
50. Casey D.A. Depression in the elderly. South Med. J. 87:1994;559-563.
51. Cassano G.B., Musetti L., Soriani A., Savino M. The pharmacologic treatment of depression: drug selection criteria. Pharmacopsychiatry. 26:1993;17-23.
52. Charatan F.B. The aged. Hankoff L.D. 'Suicide: Theory and Clinical Aspects'. 1979;253-262 P.S.G. Publishing, Littleton, MA.
53. Ciarcha G., Smokcum R.W.J., Stephenson J.D., Weiramanthri T.B. Effects of some atypical antidepressants on β-adrenoceptor binding and adenylate cyclase activity in the rat forebrain. Eur. J. Pharmacol. 108:1985;1-7.
54. Chiang C., Aston-Jones G. A 5-hydroxytryptamine-2 agonist augments g-aminobutyric acid and excitatory amino acid inputs to noradrenergic locus coeruleus neurons. Neurosci. 54:1993;409-420.
55. 4 dopamine receptor mediated signaling events determined in transfected Chinese hamster ovary cells. J. Biol. Chem. 269:1994;11813-11819.
56. 2 dopamine receptors. Molec. Pharmacol. 45:1994;51-60.
57. Clark D.W.J. Genetically determined variability in acetylation and oxidation: therapeutic implications. Drugs. 29:1985;342-375.
58. Clerc, G.E., Ruimy, P. and Verdeau-Pailles on behalf of the Venlafaxine French Inpatient Study Group., 1994. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Intern. Clin. Psychopharm. 9, 139-143.
59. 2A/2C receptor blockade by amesergide fully attenuates prolactin response to d-fenfluramine challenge in physically healthy human subjects. Psychopharmacol. 126:1996;24-30.
60. Cohen A.I., Todd R.D., Harmon S., O'Malley K.L. Photoreceptors of mouse retinas possess D4 receptors coupled to adenylate cyclase. Proc. Natl. Acad. Sci. U.S.A. 89:1992;12093-12097.
61. Copeland J.R.M., Dewey M.E., Wood N., Searle R., Davidson I.A., McWilliam C. Range of mental illness among the elderly in the community: prevalence in Liverpool using the GMS-AGECAT package. Br. J. Psychiatry. 150:1987;815-823.
62. Cosi V., Citterio A., Ratti M.T., Romani A. Pavia memory project: study design and first results. Ital. J. Neurol. Sci. 16:1995;141-148.
63. 3H ]-spiperone labels dopamine receptors in pituitary and brain. Eur. J. Pharmacol. 46:1977;377-381.
64. Crewe H.K., Lennard M.S., Tucker G.T., Woods F.R., Haddock R.E. The effect of selective serotonin reuptake inhibitors on cytochrome P450 2D6 (CYP2D6) activity in human liver microsomes. Br. J. Clin. Pharmacol. 34:1992;262-265.
65. Cross J.A., Horton R.W. Are increases in GABAB receptors consistent findings following chronic antidepressant administration? Eur. J. Pharmacol. 141:1987;159-162.
66. Curran E.J., Watson S.J. Jr. Dopamine receptor mRNA expression patterns by opioid peptide cells in the nucleus accumbens of the rat: a double in situ hybridization study. J. Compl. Neurol. 361:1995;57-76.
67. 3H ] imipramine. J. Pharmacol. and Exp. Ther. 242:1987;364-371.
68. Danion J.M. Antidepressive agents and memory. Encephale. 19:1993;417-422.
69. Davis J.M., Janicak P.G. Risperidone: a new, novel (and better?) antipsychotic. Psychiatric Ann. 26:1996;78-87.
70. Dawling S., Crome P., Braithwaite R.A. Pharmacokinetics of single oral doses of nortriptyline in depressed elderly hospital patients and young eldelry volunteers. Clin. Pharmacokin. 5:1980;394-401.
71. De Angelis L. Lithium treatment and the geriatric population. Int. J. Clin. Pharmac., Ther. and Toxic. 28:1990;394-398.
72. De Leo, D., Pavan, L., 1993. Terapia farmacologica dei disturbi dell'umore. In: Crepaldi, G., (Ed.), Trattato di Gerontologia e Geriatria, UTET, pp. 990-1008.
73. Delle Chiaie R., Caliari P. Sintomatologia depressiva attenuata ad andamento protratto: razionale per l'uso dell'amisulpride. Cervello e Farmaci, Riv. Psich. 6:1997;77.
74. 1-like receptors from Gallus Domesticus. J. Biol. Chem. 270:1995;72-76.
75. Demling J. Mianserin: pharmacology and clinical aspects of an effective antidepressive agent. Fortschr. Med. 111:1993;497-500.
76. Demotes-Mainard F., Galley P., Manciet G., Vinson G., Salvadori C. Pharmacokinetics of the antidepressant tianeptine at steady state in the elderly. J. Clin. Pharmacol. 31:1991;174-178.
77. DeVane C.L. Pharmacogenetics and metabolism of newer antidepressant agents. J. Clin. Psychiatry. 55:(12 Suppl.):1994;38-45.
78. De Waal M.W.M., Stolk J., van Marwijk H.W.J., Springer M.P. Prescribing antidepressant drugs in primary care. Nederlands Tijdschrift Geneeskunde. 140:1996;2131-2134.
79. Diaz J., Levesque D., Griffon N., Lammer C.H., Martres M., Schwartz J.C., Sokoloff P. Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain. Neuroscience. 65:1995;731-745.
80. Dixon R.A.F., Kobilka B.K., Strader D.J., Benovic J.L., Dohlman H.G., Frielle T., Bolanowski M.A., Bennett G.D., Rands E., Diehl R.E., Mumford R.A., Slater E.E., Sigal I.A., Caron M.G., Lefkowitz R.J., Strader C.D. Cloning of the gene and cDNA for mammalian b-adrenergic receptor and homology with rhodopsin. Nature. 321:1986;75-79.
81. Dubini A., Bosc M., Polin V. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J. Psychopharmacol. 11:(4):1997;517-523.
82. Dubovsky S.L. Calcium antagonists: a new class of psychiatric drugs? Psychiatr. Ann. 16:1986;724-728.
83. Dufouil C., Dartigues J.F., Fuhrer R. Symptomes depressifs chez les personnes agees: comparison entre des populations rurales et urbaines. Rev. Epidemiol. Sante Publique. 43:1995;308-315.
84. Dugas J.E., Weber S.S. Amoxapine. Drug Intell. Clin. Pharm. 16:1982;199-204.
85. Duman R.S., Vaidya V.A., Nibuya M. Stress, antidepressant treatments and neurotrophic factors: molecular and cellular mechanisms. Neuroscientist. 1:1995;351-360.
86. Duriot J.F., Dutertre J.P., Grenier J.M., Autret A., Martin A. Amineptin dependence and iatrogenic acne. Review of the literature apropos of a case. Ann. Med. Psychol. 149:1991;795-797.
87. Egberts A.C.G., Leufkens H.G.M., Hofman A., Hoes A.W. Incidence of antidepressant drug use in older adults and association with chronic diseases: the Rotterdam study. Intern. Clin. Psychopharmacol. 12:1997;217-223.
88. Eisenberg L. Treating depression and anxiety in primary care. Closing the gap between knowledge and practice. New Eng. J. Med. 326:1992;1080-1083.
89. el-Yazigi A., Chaleby K. Steady-state kinetics of doxepin and imipramine in Saudi patients with interethnic comparison. Psychopharmacol. 95:1988;63-67.
90. Ellison J.M., Milofsky J.E., Ely E. Fluoxetine-induced bradycardia and syncope in two patients. J. Clin. Psychiatry. 51:1990;385-386.
91. Ereshefsky L., Tran-Johnson T., Davis C.M., Leroy A.P. Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect evaluation of doxepin and imipramine - new data and review. Clin. Chem. 34:1988;863-880.
92. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J. Clin. Psychopharmacol. 16:1996;37S-53S.
93. Ernst E., Rand J.I., Barnes J., Stevinson C. Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). Eur. J. Clin. Pharmacol. 54:1998;589-594.
94. Ernst E., Rand J.I., Stevinson C. Complementary therapies for depression: an overview. Arch. Gen. Psychiatry. 55:1998;1026-1032.
95. Evans S., Katona C. Epidemiology of depressive symptoms in elderly primary care attenders. Dementia. 4:1993;327-333.
96. Fava M., Borus J.S., Alpert J.E., Nierenberg A.A., Rosenbaum J.F., Bottiglieri T. Folate, B12 and homocysteine in major depressive disorder. Am. J. Psychiatry. 154:(3):1997;426-428.
97. Feighner J.P., Cohn J.B. Double-blind comparative trials of fluoxetine and doxepine in geriatric patients with major depressive disorder. J. Clin. Psychiatry. 46:1985;20-25.
98. Felder C.C., Williams H.L., Axelrod J. A trasduction pathway associated with receptors coupled to the inhibitory guanine nucleotide binding protein G1 that amplifies ATP-mediated arachidonic acid release. Proc. Natl. Acad. Sci. U.S.A. 88:1991;6477-6480.
99. Feighner J.P., Boyer W.F., Tyler D.L., Neborsky R.J. Adverse consequences of fluoxetine-MAOI combination therapy. J. Clin. Psychiatry. 51:1990;222-225.
100. Fields E.D. Nomifensine maleate. Drug Intell. Clin. Pharm. 16:1982;547-552.
101. Finlayson R.E., Martin L.M. Recognition and management of depression in the elderly. Mayo Clin. Proc. 57:1982;115-120.
102. Fisch C. Effects of fluoxetine on the electrocardiogram. J. Clin. Psychiatry. 46:1985;42-44.
103. Fisch C., Knoebel S.B. Electrocardiographic findings in sertraline depression trials. Drug Invest. 4:1992;305-312.
104. Flint A.J., Rifat S.L. A prospective study of lithium augmentation in antidepressant-resistant geriatric depression. J. Clin. Psychopharmacol. 14:1994;353-356.
105. Forsell Y., Jorm A.F., Von Strauss E., Winblad B. Prevalence and correlates of depression in a population of nonagenarians. Br. J. Psychiatry. 167:1995;61-64.
106. 1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission. Proc. Natl. Acad. Sci. 88:1991;3772-3776.
107. Frerichs R.R., Aneshensel C.S., Clark V.A. Prevalence of depression in Los Angeles County. Am. J. Epidemiol. 133:1981;691-699.
108. Friedlander A.H., Kawakami K.K., Ganzell S., Fitten L.J. Dental management of the geriatric patient with major depression. Spec. Care Dentist. 13:1993;249-253.
109. Friedman J.R., Norman D.C., Yoshikawa T.T. Correlation of estimated renal function parameters versus 24-h creatinine clearance in ambulatory elderly. JAGS. 37:1989;145-149.
110. Furlanut M., Benetello P. The pharmacokynetics of tryciclic antidepressant drugs in the elderly. Pharmacol. Res. 22:1990;15-25.
111. Fyer A.J., Gorman J.M. Phenelzine in social phobia. J. Clin. Psychopharmacol. 6:1986;93-98.
112. Gainsborough N., Nelson M.L., Maskrey V., Swift C.G., Jackson S.H. The pharmacokinetics and pharmacodynamics of medifoxamine after oral administration in healthy elderly volunteers. Eur. J. Clin. Pharmacol. 46:1994;163-166.
113. Galeotta G., Paoletti V., Mammarella A., Falaschi R. La terapia farmacologica nel paziente anziano. Clin. Ter. 135:1990;181-192.
114. Garattini S., Samanin R. Biochemical hypothesis on antidepressant drugs: a guide for clinicians or a toy for pharmacologists? Psychol. Med. 18:1988;287-304.
115. Gardner S.F., Rutherford W.F., Munger M.A., Panacek E.A. Drug-induced supraventricular tachycardia: a case report of fluoxetine. Ann. Emerg. Med. 20:1991;194-197.
116. 2 receptor-mediated excitation of interneurons in piriform cortex: antagonism by atypical antipsychotic drugs. Neurosci. 58:1994;515-525.
117. Gerard C., Martres M.P., Lefevre K. Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system. Brain Res. 746:1997;207-219.
118. Geretsegger C., Bohmer F., Ludwig M. Paroxetine in the elderly depressed patients: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects. Int. Clin. Psychopharmacol. 9:1994;25-29.
119. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Mosma F.J. Jr, Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of nigrostriatal and striatopallidal neurons. Science. 250:1990;1429-1432.
120. Gerson S.C., Plotkin D.A., Jarvik L.F. Antidepressant drug studies, 1964 to 1986: empirical evidence for aging patients. J. Clin. Psychopharmacol. 8:1988;311-322.
121. Ghose K., Spragg B.P. Pharmacokinetics of lofepramine and amitriptyline in elderly healthy subjects. Int. Clin. Psychopharmacol. 4:1989;201-215.
122. Gingrich J.A., Caron M.G. Recent advances in the molecular biology of dopamine receptors. A. Rev. Neurosci. 16:1993;299-321.
123. Glassman A.H., Bigger J.T. Jr. Cardiovascular effects of therapeutic doses of tricyclic antidepressants: a review. Arch. Gen. Psychiatry. 38:1981;815-820.
124. Glassman A.H., Preud'homme X.A. Review of the cardiovascular effects of heterocyclic antidepressants. J. Clin. Psychiatry. 54:1993;16-22.
125. Glassman A.H., Roose S.P. Risks of antidepressants in the elderly: tricyclic antidepressants and arrhythmia-revising risks. Gerontology. 40:1994;15-20.
126. Glassmann A.H. Citalopram toxicity (Letter) Lancet. 350:1997;818.
127. Glassmann A.H. Cardiovascular effects of antidepressant drugs: updated. Int. Clin. Psychopharmac. 13:1998;25-30.
128. Goa K.L., Ross S.R., Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 46:1993;152-176.
129. Goldberg E.L., Van Natta P., Comstock G.W. Depressive symptoms, social networks and social support of elderly women. Am. J. Epidemiol. 121:1985;448-455.
130. Gonzalez F.J., Skoda R.C., Kinenza S. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 331:1988;442-446.
131. Gottfries C.G. Neurochemical aspects of aging and diseases with cognitive impairment. J. Neurosci. Res. 27:1990;541-547.
132. Gottfries C.G. Is there a difference between elderly and younger patients with regard to the symptomatology and aetiology of depression? Int. Clin. Psychopharmacol. 13:(5):1998;S13-S18.
133. 5 dopamine receptor genes: a functional receptor and two pseudogenes. Proc. Natl. Acad. Sci. U.S.A. 88:1991;9175-9179.
134. Greenblatt D.J., Sellers E.M., Shader R.I. Drug disposition in old age. New Engl. J. Med. 306:1982;1081-1088.
135. Greenblatt D.J., Friedman H., Burstein E.S., Scavone J.M., Biyden G.T., Ochs H.R., Miller L.G., Harmatz J.S., Shader R.I. Trazodone kinetics: effect of age, gender and obesity. Clin. Pharmac. and Ther. 42:1987;193-200.
136. Greene D.S., Barbhaiya R.H. Clinical pharmacokinetics of nefazodone. Clin. Pharmacokinet. 33:1997;260-275.
137. Guentert T.W., Tucker G., Korn A., Prefen J.P., Haefelfinger P., Schoerlin M.P. Pharmacokinetics of meclobemide after single and multiple oral dosing with 150 mg three times daily for 15 days. Acta Psychiatr. Scand. 82:1990;91-93.
138. Guarnieri, L., Sacchetti, E., 1998. Trattamento farmacologico della depressione nell'anziano: una rassegna. In: Vella, G., Siracusano, A. (Eds.), La depressione nell'anziano. Il Pensiero Scientifico Ed., Roma, suppl. 2, vol. 4 NOOζ, pp. 55-76.
139. Gusella J.F. Location cloning strategy for charavterizing genetic defects in Huntington's disease and Alzheimer disease. FASEB J. 3:1989;2036-2041.
140. Halaris A. Antidepressant drug therapy in the elderly: enhancing safety and compliance. Int. J. Psychiatry Med. 16:1987;1-19.
141. Halper J.P., Mann J.J. Cardiovascular effects of antidepressant medications. Br. J. Psychiatry. 153:1988;87-98.
142. Haria M., Fitton A., McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potetial in other disorders. Drugs Aging. 4:1994;331-355.
143. Harlow S.D., Goldberg E.L., Comstock G.W. A longitudinal study of risk factors for depressive symptomatology in elderly widowed and married women. Am. J. Epidemiol. 134:1991;526-538.
144. Harris M.G., Benfield P. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in older patients with depressive illness. Drugs Aging. 6:1995;64-84.
145. Hasin D., Link B. Age and recognition of depression: implications for a cohort effect in major depression. Psychol. Med. 18:1988;683-688.
146. Hauger R.L., Scheinin M., Siever L.J. Dissociation of norepinephrine turnover from α2 responces after clorgyline. Clin. Pharm. Ther. 43:1988;32-38.
147. 2 receptor are functionally distinct: expression of the cloned D2a and D2b subtypes in a heterologous cell line. Molec. Endocrinol. 6:1992;920-926.
148. 2 dopamine receptor proteins in the dorsal striatum and their synaptic relationship with motor corticostriatal afferents. J. Neurosci. 15:1995;5222-5237.
149. Hewick D.S., Newbury P., Hopwood S., Naylor G., Moody J. Age as a factor affecting lithium therapy. Br. J. Clin. Pharmac. 4:1977;201-205.
150. Hiemke C. Paroxetine: pharmacokinetics and pharmacodynamics. Fortschr. Neurol. Psychiatr. 62:1994;2-8.
151. Holliday S.M., Plosker G.L. Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy. Drugs Aging. 3:1993;278-299.
152. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 46:1994;157-203.
153. Hoyer D., Martin G.R. Classification and nomenclature of 5-HT receptors: a comment on current issues. Behav. Brain Res. 73:1996;263-268.
154. Hsyu P.H., Singh A., Giargiari T.D., Dunn J.A., Ascher J.A., Johnston J.A. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus non smokers. J. Clin. Pharmacol. 37:1997;737-743.
155. Hyttel J. Citalopram: pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 6:1982;277-295.
156. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Intern. Clin. Psychopharmacol. 9:1994;19-26.
157. Hyttel J., Larsen J.J. Serotonin-selective antidepressants. Acta Pharmacol. Toxicol. 56:(1):1985;146-153.
158. Hyttel J., Arnt J., Bogeso K., Christensen A.V., Larsen J.J., Lembol H.L., Meier E., Sanchez C. Neurochemical and behavioural profile of Lu 17-133, (±)-trans-4-[3-(3,4-dichlorophenyl)-indan-1-yl]-1-piperazineethanol, an inhibitor of the uptake of dopamine and noradrenaline. Drug Develop. Res. 13:1988;213-230.
159. Hubner W.D., Lande S., Podzuweit H. Hypericum treatment of mild depression with somatic symptoms. J. Geriatr. Psychiatry Neurol. 7:(1):1994;12-14.
160. Isaccson G., Redfors I., Wasserman D., Bergman U. Choice of antidepressants: questionnaire survey of psychiatrists and general practitioners in two areas of Sweden. B. M. J. 309:1994;1546-1549.
161. Jaber M., Robinson S.W., Missale C., Caron M.G. Dopamine recptors and brain function. Neuropharmacol. 35:1996;1503-1519.
162. Jackson D.M., Westlind-Danielson A. Dopamine receptors: molecular biology, biochemistry and behavioral aspects. Pharmacol. Ther. 64:1994;291-369.
163. Jarvik L.F., Mitz J., Steuer J. Treating geriatric depression. JAGS. 30:1982;713-717.
164. Jefferson J.W. A review of the cardiovascular effects and toxicity of tricyclic antidepressant. Psychosom. Med. 37:1975;160-179.
165. Jeppesen U., Gram L.F., Vistisen K., Loft S., Poulsen H.E., Brosen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur. J. Clin. Pharmacol. 51:1996;73-78.
166. Johnson A.M. The comparative pharmacological properties of selective serotonin reuptake inhibitors in animals. Feighner J.P., Boyer W.F. Selective Serotonin Reuptake Inhibitors: Perspectives in Psychiatry. vol. 1:1991;37-70 Wiley, Chichester UK.
167. Jones G.L., Wimbihsh G.H. Phenytoin. Frey H.H., Janz D. Handbook of Experimental Pharmacology. 4:1985;195-226 Raven Press, New York.
168. Josey E.S., Tackett R.L. St. John's wort: a new alternative for depression? Int. J. Clin. Pharmacol. Ther. 37:1999;111-119.
169. Kan J.P., Strolin Benedetti M. Antagonism between long acting monoamineoxidase inhibitors (MAOI) and MD 780515, a new specific and reversible MAOI. Life Sci. 26:1980;2165-2171.
170. 2 dopamine receptor mediate the potentiation of arachidonic acid release in Chinese hamster ovary cells. Molec. Pharmacol. 39:1991;364-369.
171. Kasper S., Praschak-Rieder N., Tauscher J., Wolf R. A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Saf. 17:1997;251-264.
172. Katona C.L.E. Depression in Old Age. 1994;9-41 Wiley, Chichester, UK.
173. Katz I.R. Drug treatment of depression in the frail elderly: discussion of the NIH consensus development conference on the diagnosis and treatment of depression in late life. Psychopharmacol. Bull. 29:1993;101-108.
174. Katz I.R., Streim J., Parmeles P. Prevention of depression, recurrence and complications in late life. Prev. Med. 23:1994;743-750.
175. Kebabian J.W., Calne D.B. Multiple receptors for dopamine. Nature. 277:1979;93-96.
176. Kelly C., Roche S., Naguib M., Webb S., Roberts M., Pitt B. A prospective evaluation of the hepatotoxicity of lofepramine in the elderly. Int. Clin. Psychopharmacol. 8:1993;83-86.
177. Kennedy G.J., Kelman H.R., Thomas C., Wisniewski W., Metz H., Bijur P.E. Hierarchy of characteristics associated with depressive symptoms in an urban elderly sample. Am. J. Psychiatry. 146:1989;220-225.
178. Kincaid R.L., McMullin M.M., Crookham S.B., Rieders F. Report of a fluoxetine fatality. J. Anal. Toxicol. 14:1990;327-329.
179. Kinney J.L. Nomifensine maleate: a new second-generation antidepressant. Clin. Pharm. 4:1985;625-636.
180. Kirby M., Bruce I., Radic A., Coakley D., Lawlor B.A. Mental disorders among the community-dwelling elderly in Dublin. Br. J. Psychiatry. 171:1997;369-372.
181. Kivela S.L., Pahkala K., Laippala P. Prevalence of depression in an elderly population in Finland. Acta Psychiatr. Scand. 78:1988;401-413.
182. 3H ]SCH 23390 binding sites in the rat striatum and limbic system. Eur. J. Pharmacol. 139:1987;163-169.
183. Koenig H.G. Treatment considerations for the depressed geriatric medical patient. Drugs Aging. 1:1991;266-278.
184. Koenig H.G., Blazer D.G. Epidemiology of geriatric affective disorders. Clin. Geriatr. Med. 8:1992;235-251.
185. Korn A., Da Prada M., Raffesberg W., Gasic S., Eichler H.G. Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine. J. Cardiovasc. Pharmacol. 11:1988;17-23.
186. Kovala T., Leppavuori A., Putkonen P. Sleep in cats after a new 5-HT uptake inhibiting drug: Lu 10-171. Acta Physiol. Scand. 102:1987;74A-75A.
187. Krause N., Liang J., Yatomi N. Satisfaction with social support and depressive symptoms: a panel analysis. Psychol. Aging. 4:1989;88-97.
188. Kukull W.A., Koepsell T.D., Inui T.S., Borson S., Okimoto J., Raskind M.A., Gale J.L. Depression and physical illness among elderly general medical clinic patients. J. Affect. Dis. 10:1986;153-162.
189. Laakmann G., Schule C., Baghai T., Kieser M. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry. 31:(1):1998;54-59.
190. Laghrissi-Thode F., Wagner W.R., Pollock B.G., Johnson P.C., Finkel M.S. Elevated platelet factor 4 and β-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol. Psychiatry. 42:1997;290-295.
191. Lamy P.P. Geriatric drug therapy. Am. Fam. Phys. 34:1986;118-124.
192. Lancaster S.G., Gonzalez J.P. Lofepramine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 37:1989;123-140.
193. Lands A.M., Arnold A., McAuliff J.P., Luduena F.P., Brown T.G. Differentiation of receptor systems activated by sympathomimetic amines. Nature. 214:1967;597-598.
194. Langer S.Z. Presynaptic regulation of catecholamine release. Brit. J. Pharmacol. 60:1974;481-497.
195. 3H ]DMI binding associated with neuronal noradrenaline uptake in the periphery and the central nervous system. Eur. J. Pharmacol. 72:1981;423-424.
196. Lecrubier Y. Is depression under-recognized and undertreated? Int. Clin. Psychopharmacol. 13:(5):1998;S1-S2.
197. Leinonen E., Koponen H., Lepola U. Delirium during fluoxetine treatment: a case report. Ann. Clin. Psychiatry. 5:1993;255-257.
198. Leinonen E., Koponen H., Lepola U. Serum mianserin and ageing. Prog. Neuropsychopharmacol. Biol. Psychiatry. 18:1994;833-845.
199. Lejoyeux M. Use of serotonin (5-hydroxytryptamine) reuptake inhibitors in the treatment of alcoholism. Alcohol Alcohol. 31:1996;69-75.
200. Lemberger L., Bergstrom R.F., Wolen R.F., Farid N.A., Enas G.G., Aronoff G.R. Fluoxetine: clinical pharmacology and physiologic disposition. J. Clin. Psychiatry. 46:1985;14-19.
201. 2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J. Comp. Neurol. 355:1995;418-426.
202. Le Moine C., Normand E., Guitteny A.F., Fouque B., Teoule R., Bloch B. Dopamine receptor gene expression by enkephalin neurons in rat forebrain. Proc. Natl. Acad. Sci. U.S.A. 87:1990;230-234.
203. 1 dopamine receptor gene. Proc. Natl. Acad. Sci. U.S.A. 88:1991;4205-4209.
204. Lepine J.P., Bouchez S. Epidemiology of depression in the elderly. Int. Clin. Psychopharmac. 13:1998;S7-S12.
205. Leppik I.E. Metabolism of antiepileptic medication: newborn to elderly. Epilepsia. 33:1992;S32-S40.
206. Lester D. Depression, suicidal preoccupation and scores on the Rokeach Value Survey: a correction. Psychol. Rep. 73:1993;1202.
207. Limbird L.E. Receptors linked to inhibition of adenylate cyclase: additional signaling mechanisms. FASEB. 2:1988;2686-2695.
208. Lim H.L. A practical approach to the management of depression. Singapore Med. J. 34:1993;449-451.
209. Linden M., Kurtz G., Baltes M.M., Geiselmann B., Lang F.R., Reischies F.M., Helmchen H. Depression in the very elderly. Nervenarzt. 69:1998;27-37.
210. Lindesay J., Briggs K., Murphy E. The Guy's age concern survey. Prevalence rates of cognitive impairment, depression and anxiety in an urban elderly community. Br. J. Psychiatry. 155:1989;317-329.
211. Livingston G., Hawkins A., Graham N., Blizard B., Mann A. The gospel oak study: prevalence rates of dementia, depression and activity limitation among elderly residents in Inner London. Psychol. Med. 20:1990;137-146.
212. Luo H., Richardson J.S. A pharmacological comparison of citalopram, a bicyclic serotonin uptake inhibitor, with traditional tricyclic antidepressants. Int. Clin. Psychopharmacol. 8:1993;3-12.
213. MacDonald A.J.D. Do general practitioner 'miss' depression in elderly patients? B. M. J. 292:1986;1365-1367.
214. Maguire K.P., Norman T.R., McIntyre I., Burrows G.D. Clinical pharmacokinetics of dothiepin. Single-dose kinetics in patients and prediction of steady-state concentrations. Clin. Pharmacokinet. 8:1983;179-185.
215. Maguire K., Pereira A., Tiller J. Meclobemide pharmacokinetics in depressed patients: lack of age effect. Hum. Psychopharmacol. 6:1991;249-252.
216. 2 agonist. J. Neur. Transm. 78:1989;1-8.
217. 2 receptor. Eur. J. Pharmacol. 227:1992;205-214.
218. Markianos M., Alevizos V., Stafanis C. Plasma sex hormones and urinary biogenic amine metabolites during treatment of male depressed patients with the monoamine oxidase inhibitor meclobemide. Neuroendocrinol. Lett. 13:1991;49-55.
219. Martin A.J., Tebbs V.M., Ashford J.J. Affective disorders in general practice. Treatment of 6000 patients with fluvoxamine. Pharmatherapeutica. 5:1987;40-49.
220. Martinez B., Kasper S., Ruhrmann S., Moller H.J. Hypericum in the treatment of seasonal affective disorders. J. Geriatr. Psychiatry Neurol. 7:(Suppl. 1):1994;29-33.
221. McLean M.J. Gabapentin. Chemistry, absorption, distribution and excretion. Levy R.H., Mattson R.H., Meldrum B.S. Antiepileptic Drugs. 4th ed:1995;843-849 Raven Press, New York.
222. 4 dopamine receptors in HEK293 cells. J. Recep. Signal Trans. 15:1995;267-281.
223. McManis P.G., Talley N.J. Nausea and vomiting associated with selective serotonin reuptake inhibitors: incidence, mechanisms and management. CNS Drugs. 8:1997;394-401.
224. 2 dopamine receptor mRNA in the rat brain. Proc. Natl. Acad. Sci. U.S.A. 86:1989;7625-7628.
225. 5 dopamine receptor mRNA in the rat brain. Neurosci. Lett. 145:1992;209-212.
226. Melia K.F., Spealman R.D. Pharmacological characterization of the discriminative-stimulus effects of GBR 12909. J. Pharmacol. Exp. Ther. 258:1991;626-632.
227. 3H ]imipramine to human platelet membranes. Eur. J. Pharmacol. 96:1983;303-309.
228. Mendlewicz J. Care of depression in older patients. Introduction. Int. Clin. Psychopharmacol. 13:(5):1998;S1-S2.
229. 2 receptor by in situ hybridization histochemistry. Correlation with the distribution of receptor sites. Brain Res. 524:1990;139-143.
230. Miller A.L. St. John's wort (Hypericum perforatum): clinical effects on depression and other conditions. Altern. Med. Rev. 3:1998;18-26.
231. Mitchell A.J., Dening T.R. Depression-related cognitive impairment: possibilities for its pharmacological treatment. J. Affective Disord. 36:1996;79-87.
232. Montamat S.C., Cusack B.J., Yestal R.E. Management of drug therapy in the elderly. New Engl. Med. 321:1989;303-309.
233. Monti J.M., Alterwain P., Monti D. The effect of meclobemide on nocturnal sleep of depressed patients. J. Affect. Disord. 20:1990;201-208.
234. 2 receptor linked to adenylyl cyclase activation. Proc. Natl. Acad. Sci. U.S.A. 88:1991;3135-3139.
235. 2 receptors and G-proteins. Mol. Endocrinol. 7:1993;161-170.
236. Morilak D.A., Garlow S.J., Ciaranello R.D. Immunocytochemical localization and description of neurons expressing serotonin-2 receptors in the rat brain. Neurosci. 54:1993;701-717.
237. Morocutti C., Rossi P., Morocutti A. La pseudodemenza: aspetti clinici e terapeutici. Nuova Rivista di Neurologia. 8:1998;13-26.
238. Morselli P.L., Rossi L. Carbamazepine absorption, distribution and excretion. Woodbury D.M., Penry J.K., Pippenger C.E. Antiepileptic Drugs. 2nd ed:1982;465-482 Raven Press, New York.
239. 1-adrenoceptors in vascular smooth muscle. Brit. J. Pharmacol. 99:1990;197-201.
240. Murphy E. The prognosis of depression in old age. Br. J. Psych. 142:1983;11-119.
241. Murphy J.M., Olivier D.C., Monson R.R., Sobol A.M., Leighton A. Incidence of depression and anxiety. Am. J. Publ. Health. 78:1988;534-540.
242. Murphy B.E.P., Dhar V., Ghadirian A.M. Response to steroid suppression in major depression resistant to antidepressant therapy. J. Clin. Psychopharmacol. 11:1991;121-126.
243. Murphy D.L., Mitchell P.B., Potter W.Z. Novel pharmacological approaches to the treatment of depression. Bloom F.E., Kupfer D.J. Psychopharmacology: The Fourth Generation of Progress. 1995;1143-1153 Lippincott-Raven Healthcare.
244. Murrell S.A., Himmelfarb S., Wright K. Prevalence of depression and its correlates in older adults. Am. J. Epidemiol. 117:1983;173-185.
245. Nair N.P.V., Ahmed S.K., Ng Ying Kin N.M.K., West T.E.G. Reversible and selective inhibitors of monoamine oxidase A in the treatment of depressed elderly patients. Acta Psychiatr. Scand. 91:1995;28-35.
246. Nemeroff C.B. Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression. J. Clin. Psychopharmacol. 13:1993;10S-17S.
247. Nichols A.J., Ruffolo R.R. Functions mediated by α-adrenoceptors. Ruffolo R.R. Jr. α-Adrenoceptors: Molecular Biology, Biochemistry and Pharmacology. Prog. Basic Clin. Pharmacol. vol. 8:1991;115-179 Karger, Basel.
248. Nies A., Robinson D.S., Friedman M.J., Green R., Cooper T.B., Ravaris C.L., Ives J.O. Relationship between age and tricyclic antidepressant plasma levels. Am. J. Psychiatry. 134:1977;790-793.
249. Okwumabua J.O., Baker F.M., Wong S.P., Pilgram B.O. Characteristics of depressive symptoms in elderly urban and rural African Americans. J. Gerontol. 52A:1997;241-246.
250. 4 receptor: sequence, gene structure and demonstration of expression in the cardiovascular system. The New Biologist. 4:1992;137-146.
251. Ostrom M., Eriksson A., Thorson J., Spigset O. Fatal overdose with citalopram. Lancet. 348:1996;339-340.
252. Owmank T.E., Berkman L.F., Kasl S., Freeman D.H., Barratt J. Social support and depressive symptoms in the elderly. Am. J. Epidemiol. 135:1992;356-368.
253. Oxenkrug G.F., McCauley R., McIntyre I.M., Filipwicz C. Selective inhibition of MAO-A but not MAO-B activity increases rat pineal melatonin. J. Neural. Transm. 61:1985;265-270.
254. Palmer K.J., Benfield P. Fluvoxamine - an overview of its pharmacological properties and review of its therapeutic potential in non-depressive disorders. CNS Drugs. 1:1994;57-87.
255. Palsson, S., Skoog, I. 1997 The epidemiology of affective disorders in the elderly. A review. Proceedings of the Lundbeck Symposium Nice, France, 22-27 June 1997.
256. Parmelee P.A., Katz I.R., Lawton M.P. Depression among instituzionalized aged: assessment and prevalence estimation. J. Gerontol. 44:1989;22-29.
257. Pazos A., Cortes R., Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. Serotonin-2 receptors. Brain Res. 346:1985;231-249.
258. Perucca E., Grimaldi R., Gatti G., Pirracchio S., Crema F., Frigo G.M. Pharmacokinetics of valproic acid in the elderly. Br. J. Clin. Pharmacol. 17:1984;665-669.
259. Pilc A., Lloyd K.G. Chronic antidepressants and GABA 'B' receptors. A GABA hypothesys of antidepressant drug action. Life Sci. 35:1984;2149-2154.
260. 3H ]Citalopram binding to brain platelet membranes of human and rat. J. Neurochem. 56:1991;248-252.
261. 3H ]citalopram binding to the 5-HT transporter from brain and platelets. Eur. J. Pharmacol. 206:1991;243-250.
262. Pollock B.G., Laghrissi-Thode F., Wagner W.R., Finkel M., Johnson P.C. Increased PF4 and β-TG in depressed patients with ischemic feart disease. Scientific abstract of the 34th Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico:1995.
263. Porter R.J., Meldrum B.S. Antiepileptic drugs. Katzung B.G. Basic and Clinical Pharmacology. 1995;361-380 Appleton and Lange, East Norwalk, CT.
264. Post R.M., Frye M.A., Denicoff K.D., Leverich G.S., Kimbrell T.A., Dunn R.T. Beyond lithium in the treatment of bipolar illness. Neuropsychopharmacol. 19:1998;206-219.
265. Potter W.Z., Calil H.M., Manian A.A., Zavadil A.P., Goodwin F.K. Hydroxylated metabolites of tricyclic antidepressants. Biol. Psyc. 14:1979;601-613.
266. Potter L.B., Rogler L.H., Moscicki E.K. Depression among Puerto Ricans in New York city: the Hispanic health and nutrition examination survey. Soc. Psychiatry Psychiatr. Epidemiol. 30:1995;185-193.
267. Potter W.Z., Rudorfer M.V., Manji H. The pharmacologic treatment of depression. N. Engl. J. Med. 325:1991;633-642.
268. Price L.H., Malison R.T., McDougle C.J., Pelton G.H. Antiglucocorticoids as treatments for depression. Rationale for use and therapeutic potential. CNS Drugs. 5:1996;311-320.
269. Prince M.J., Harwood R.H., Blizard R.A., Thomas A., Mann A.H. Impairment, disability, and handicap as risk factors for depression in old age. The gospel oak project V. Psychol. Med. 27:1997;311-321.
270. Puzantian T. Mirtazapine, an antidepressant. Am. J. Health Syst. Pharm. 55:1998;44-49.
271. Radloff L.S. The CES-D scale: a self-report depression scale for research in the general population. Appl. Psychol. Measurement. 1:1977;385-401.
272. 3H ]imipramine binding sites in rat lung are associated with a non-neuronal uptake site for serotonin. Eur. J. Pharmacol. 94:1983;345-348.
273. 3H ]desipramine binding in the peripheral and central nervous system: a specific site associated with the neuronal uptake of noradrenaline. Eur. J. Pharmacol. 78:1982;345-351.
274. Ramaekers J.G., Swijgman H.F., O'Hanlon J.F. The effect of meclobemide and mianserine on highway driving, psychometric performance and subjective parameters, relative to placebo. Psychopharmacology. 106:1992;562-567.
275. Rey J.M., Walter G. Hypericum perforatum (St. John's wort) in depression: pest or blessing? Med. J. Aust. 169:1998;583-586.
276. Reynolds 3rd C.F., Kupfer D.J. Depression and aging: a look to the future. Psychiatr. Serv. 59:1999;1167-1172.
277. Reynolds E.H., Preece J.M., Bailey J., Coppen A. Folate deficiency in depressive illness. Br. J. Psychiatry. 117:1970;287-292.
278. Roberts R.E., Kaplan G.A., Shema S.J., Strawbridge W.J. Does growing old increase the risk of depression. Am. J. Psychiatry. 154:1997;1384-1390.
279. Robins L.N., Helzer J.E., Crughan J.L., Ratcliff K.S. The NIMH Diagnostic Interview Schedule: its history, characteristics and validity. Arch. Gentile Psychiatry. 38:1981;381-389.
280. Roose S.P., Glassman A.H., Attia E., Woodring S., Giardina E.G.V., Bigger J.T. Jr. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am. J. Psychiatry. 155:1998;660-665.
281. Rubin E.H., Biggs J.T., Preskorn S.H. Nortriptyline pharmacokinetics and plasma levels: implications for clinical practice. J. Clin. Psyc. 46:1985;418-424.
282. Rubin, E.H., 1987. Terapia con farmaci psicotropi: precauzioni particolari nell'anziano. Minuti 5, 11-21.
283. Rudolph R., Entsuah R., Derivan A. Early clinical response in depression to venlafaxine hydrochloride. Biological Psychiatry. 29:1991;630S.
284. Ruffolo R.R. Jr. Chirality in α- and β-adrenoceptor agonists and antagonists. Tetrahedron. 47:1991;9953-9980.
285. Russel D.W., Cutrona C.E. Social support, stress and depressive symptoms among the elderly: test of process model. Psychol. Aging. 6:1991;190-201.
286. Safar M. Ageing and its effects on the cardiovascular system. Drugs. 39:1990;1-8.
287. Salvadori C., Ward C., Defrance R., Hopkins R. The pharmacokinetics of the antidepressant tianeptine and its main metabolite in healthy humans - influence of alcohol co-administration. Fundam. Clin. Pharmacol. 4:1990;115-125.
288. Salzman C. A primer on geriatric psychopharmacology. Am. J. Psyc. 139:1982;67-74.
289. Samuelian J.C., Tatossian A., Hackett D. A randomised, double-blind, parallel group comparison of venlafaxine and clomipramine in outpatients with major depression. Clin. Neuropharm. 15:1992;324B.
290. Sanders-Bush E., Sulser F. Drugs used for the treatment of affective disorders. Munson P.L. Principles of Pharmacology. 1995;309-324 Basic Concepts and Clinical Application.
291. Scheinin M., Koulu M., Karhuvaara S., Zimmer R.H. Evidence that the reversible MAO-A inhibitor meclobemide increases prolactin secretion by a serotoninergic mechanism in healthy male volunteers. Life Sci. 47:1990;1491-1499.
292. Scherschlicht R., Polc P., Schneeberger J., Steiner M., Haefely W. Selective suppression of rapid eye movement sleep (REMS) in cats by typical and atypical antidepressants. Costa E., Racagni G. Typical and Atypical Antidepressants. Molecular Mechanisms. Advances in Biochemical Psychopharmacology. vol. 31:1982;359-364 Raven Press, New York.
293. Schulman K. Conceptual problem in the assessment of depression in old age. Psychiatric J. Univ. Ottawa. 14:1989;364-371.
294. Schweitzer E., Weise C., Clary C., Fox I., Rickels K. Placebo-controlled trial of venlafaxine for the treatment of major depression. J. Clin. Psychopharmacol. 11:1991;233-236.
295. Schweitzer E., Feighner J., Mandos L.A., Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J. Clin. Psychiatry. 55:1994;104-108.
296. Seeman P., Van Tol H.H.M. Dopamine receptor pharmacology. Trends Neurosci. 15:1994;264-270.
297. Shrivastava R.K., Cohn C., Crowder J., Davidson J., Dunner D., Feighner J., Kief A., Patrick R. Long-term safety and clonical acceptability of venlafaxine and imipramine in outpatients with major depression. J. Clin. Psychopharmacol. 14:1994;322-329.
298. Small G.W. Recognition and treatment of depression in the elderly. J. Clin. Psich. 56:1991;11-22.
299. 3) as a target for neuroepileptics. Nature. 347:1990;146-151.
300. Stadel J.M., Nakada M.T. (1991). Molecular biology of β-adrenoceptors. Ruffolo R.R. Jr. β-Adrenoceptors: Molecular Biology, Biochemistry and Pharmacology. Prog. Basic Clin. Pharmacol. vol. 7:1991;44-74 Karger, Basel.
301. Stahl S.M. Antidepressants and mood stabilizers. Essential Psychopharmacology: Neuroscientific Basis and Clinical Applications. 1996;Cambridge University Press, New York. 3rd reprint.
302. Starke K., Montel H., Gayk W., Merker R. Comparison of the effects of clonidine on pre- and post-synaptic adrenoceptors in the rabbit pulmonary artery. Naunyn-Schmiedeberg's Arch. Pharmacol. 285:1974;133-150.
303. Stewart B.H., Kugler A.R., Thompson P.R., Blockbrader H.N. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of lack of proportionality between increasing dose and drug levels in plasma. Pharmacol. Res. 10:1993;276-281.
304. Stoeckel K., Pfefen J.P., Mayerson M., Schoerlin M.P., Andressen C., Onhaus E.E., Frey F., Guentert T.W. Absorption and disposition of moclobemide in patients with advanced age or reduced liver and kidney function. Acta Psychiatr. Scand. 82:1990;94-97.
305. Stollmaier W., Cimander K.F., Wagner W. Efficacy and tolerance of fluvoxamine in depressive syndromes in the practice. The results of a multicentred study on 2296 patients. Nervenheilkunde. 8:1989;247-252.
306. Sugamori K.S., Demchyshyn L.L., Chung M., Niznik H.B. D1a, D1b and D1c dopamine receptors from Xenopus laevis. Proc. Natl. Acad. Sci. U.S.A. 91:1994;10536-10540.
307. Sugrue M.F. Current concepts on the mechanism of action of antidepressant drugs. Pharm. Ther. 13:1981;219-224.
308. Sulser F., Mishra R. Regulation of central noradrenergic receptor function and its relevance to the therapy of depression. Langer S.Z., Takahashi R., Briley M. New Vistas in Depression. 1982;37-47 Pergamon Press, Oxford.
309. 1. Nature. 350:1991;614-619.
310. Surmeier D.J., Eberwine J., Wilson C.J., Cao Y., Stefani A., Kitai S.T. Dopamine recptor subtypes colocalize in rat striatoniagral neurons. Proc. Natl. Acad. Sci. U.S.A. 89:1992;10178-10182.
311. Swift M. The family history in clinical psychiatric practice. Am. J. Psychiatry. 144:1987;628-629.
312. Ten-Holt W.L., Klaassen C.H., Schrijver G. Severe hyponatremia, possibly due to inappropriate antidiuretic hormone secretion, during use of the antidepressant fluoxetine. Ned. Tijdschr. Geneeskd. 138:1994;1181-1183.
313. 1 dopamine receptor subtype: differential expression pattern in the rat brain compared with the D1a receptor. Proc. Natl. Acad. Sci. U.S.A. 88:1991;7491-7495.
314. 7 receptors in guinea pig brain. Br. J. Pharmacol. 115:1995;107-116.
315. Tomic M., Seeman P., George S.R., O'Dowd B.F. Dopamine D1 receptor mutagenesis: role of amino acids in agonist and antagonist binding. Biochem. Biophys. Res. Communun. 191:1993;1020-1027.
316. Toro P., Nores J.M., Remy J.M. Clomipramine dependence in a drug addict. First case. Presse Med. 18:1989;132.
317. Torta, R., 1999. Prontuario dei farmaci per il Sistema Nervoso Centrale, Solvay Pharma S.P.A., Torino.
318. Troy S.M., Parker V.P., Hicks D.R., Pollack G.M., Chiang S.T. Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine. J. Clin. Pharmacol. 37:1997;954-961.
319. Uhlenlhuth E.H., Balter M.B., Mellinger G.D., Cisin I.H., Clinthorne J. Symptom checklist syndromes in the general population. Correlations with psychotherapeutic drug use. Arch. Gen. Psychiatry. 40:1983;1167-1173.
320. 1 receptor enhances inositol phosphates formation in rat brain. J. Pharmacol. Exp. Ther. 253:1990;987-992.
321. Van Laar M.W., Van Willigenburg A.P., Volkerts E.R. Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions and daytime sleepiness in healthy adult and elderly subjects. J. Clin. Psychopharmacol. 15:(1):1995;30-40.
322. 4 receptor with a high affinity for the antipsychotic clozapine. Nature. 350:1991;610-614.
323. Veith R.C., Raskind M.A., Caldwell J.H. Cardiovascular effect of tricyclic antidepressants in depressed patients with chronic heart disease. N. Engl. J. Med. 306:1982;954-959.
324. Verbeeck R.K., Cardinal J.A., Wallace S.M. Effect of age and sex on the plasma binding of acid and basic drugs. Eur. J. Clin. Pharmacol. 27:1984;91-97.
325. Vetulani J., Antkiewicz-Michaluk L., Rokosz-Pelc A., Pilc A. Alpha up-beta down adrenergic regulation: a possible mechanism of action of antidepressant treatments. Polish Journal of Pharmacology and Pharmacy. 36:1984;231-248.
326. Voltz H.P., Moeller H.J. Antidepressant drug therapy in the elderly. A critical review of the controlled clinical trials conducted since 1980. Pharmacopsychiatry. 27:(3):1994;93-100.
327. Vollmer K.O., von Hodenberg A., Kolle E.U. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforsch. 36:1986;830-839.
328. Von Moltke L.L., Greenblatt D.J., Shader R.I. Clinical pharmacokinetics of antidepressants in the eldelry. Therapeutic implications. Clin. Pharmacokinet. 24:1993;141-160.
329. Vorbach E.U., Hubner W.D., Arnoldt K.T. Effectiveness and tolerance of the hypericum extract LI 160 in comparison with imipramine. Randomized double-blind study with 135 outpatients. J. Geriatr. Psychiatry Neurol. 7:1994;S19-S23.
330. Vorbach E.U., Arnoldt K.H., Hubner W.D. Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry. 30:1997;S81-S85.
331. Warrington S.J., Padgham C., Lader M. The cardiovascular effects of antidepressants. Psychol. Med. Monogr. Suppl. 16:1989;1-40.
332. Wallace S.M., Werbeeck R.K. Plasma protein binding of drugs in the elderly. Clin. Pharmacokin. 12:1987;41-72.
333. Warner J.P. Quality of life and social issues in older depressed patients. Int. Clin. Psychopharmacol. 13:(5):1998;19-24.
334. 2 receptor mRNA expression in the rat brain. Proc. Natl. Acad. Sci. U.S.A. 88:1991;1859-1863.
335. 1 beta) and its pseudogene. J. Biol. Chem. 266:1991;22427-22435.
336. Weissman M.M., Myers J.K. Affective disorders in a US urban community. Arch. Gen. Psych. 35:1978;1304-1311.
337. Weissman M.M., Myers J.K., Tischler G.L., Holzer III C.E. Jr, Leaf P.J., Orvaschel H., Brody J.A. Psychiatric disorders (DSM III) and cognitive impairment among the elderly in a US urban community. Acta Psychiatr. Scand. 71:1985;366-379.
338. Weissman M.M., Leaf P.J., Tischler G.L., Blazer D.G., Karno M., Bruce M.L., Florio L.P. Affective disorders in five United States communities. Psychol. Med. 18:1988;141-153.
339. Wesnes K.A., Simpson P.M., Christmas L., Anand R., NcClelland G.R. The effects of moclobemide on cognition. J. Neural. Transm. 28:1989;91-102.
340. West, E.D., Dally, P., 1959. Effect of iproniazid on depressive syndromes. B. M. J. 5, 491-1494.
341. Wilde M.I., Plosker G.L., Benfield P. Fluvoxamine. An updated review of its pharmacology and therapeutical use in depressive illness. Drugs. 46:1993;895-924.
342. Wilde M.I., Benfield P. Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs. 49:1995;411-439.
343. Woodburg D.M. Antiepileptic drugs: mechanism of action. Advanced in Neurology. 1980;249-303 Raven Press, New York.
344. Yang-Feng T.L., Xue F.Y., Zhong W.W., Cotecchai S., Frielle T., Caron M.G., Lefkowitz R.J., Francke U. Chromosomal organization of adrenergic receptor genes. Proc. Natl. Acad. Sci. U.S.A. 87:1990;1516-1520.
345. Yatani A., Codina J., Imoto Y., Reenes J.P., Birnbaumer L., Brown A.M. Direct regulation of mammalian cardiac calcium channels by a G-protein. Science. 238:1987;1288-1312.
346. Yesavage J., Brink T., Rose T., Lum O., Huang O., Adey V., Leirer V. Development and validation of a geriatric screening scale: a preliminary report. J. Psychiatry Res. 17:1983;37-49.
347. Zanardi R., Perez J., Tardito D. Farmacocinetica e farmacodinamica del citalopram. Smeraldi E. Farmacologia clinica del citalopram. 1999;Mosby Italia, Milano.
348. Zimmer R., Gieschke R., Firschbach R., Gasic S. Interaction studies with meclobemide. Acta psychiatr. Scand. 82:1990;84-86.
349. Zung W.W.K. A self-rating depression scale. Arch. Gen. Psychiatry. 12:1965;63-70.